Novo Nordisk | NVO - Pre Tax Profit


Novo Nordisk reported DKK25.52B in Pre-Tax Profit for its fiscal quarter ending in September of 2025.





Pre Tax Profit Change Date
ANI Pharmaceuticals USD 31.48M 18.04M Dec/2025
Aurora Cannabis CAD 11.41M 12.99M Mar/2026
Bausch Health Companies USD 56M 162M Dec/2025
Bristol-Myers Squibb USD 1.47B 1.64B Dec/2025
Canopy Growth CAD -157.96M 95.71M Mar/2026
Corcept Therapeutics USD 9.91M 5.33M Dec/2025
Drreddys Laboratories INR 2B 13.43B Mar/2026
Eli Lilly USD 8.27B 1.03B Dec/2025
GlaxoSmithKline GBP 2.14B 919M Mar/2026
Merck USD 3.42B 3.32B Dec/2025
Nektar Therapeutics USD -34.7M 2.35M Dec/2025
Novartis USD 3.84B 802M Mar/2026
Novo Nordisk DKK 33.8B 3.23B Jun/2025
Novo Nordisk DKK 25.52B 8.29B Sep/2025
Pacira USD 571K 8.95M Dec/2025
Perrigo USD -1.33B 1.35B Dec/2025
Phibro Animal Health USD 38.62M 1.26M Dec/2025
Prestige Brands USD 61.81M 7.32M Dec/2025
Sanofi EUR -1.16B 5.5B Dec/2025
Supernus Pharmaceuticals USD -5.95M 4.04M Mar/2026
Zoetis USD 761M 126M Dec/2025